So where does it fit in relation to the old GVAX work that Nemunaitis also was involved in back in 2001? http://www.unisci.com/stories/20012/0514015.htm
As I read it, he moved on from there to work with Murex Pharmaceuticals that later became Gradalis... and GVAX stayed with Cell Genesys (now Biosante), (where it came unstuck on a phase III prostate cancer trial, but, after few years, is back on again at phase II)
I realise GVAX is quite different to RNAi, but it was interesting reading the 2001 article and thinking how similar the scenario seemed to the YouTube reporting of the more recent Gradalis work on the other thread.
- Forums
- ASX - By Stock
- BLT
- combination treatments
combination treatments, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)